Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer
{{output}}
The antitumor activity demonstrated by DNA damage response inhibitors (DDRis) can be partially attributed to their capacity to enhance immune responses. However, the toxicity of DDRis to lymphocytes, particularly when a DDRi is combined with other treatments t... ...
